Topics

Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia

14:39 EDT 13 Sep 2019 | SCRIP

Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is...

      

Related Stories

 

Original Article: Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia

NEXT ARTICLE

More From BioPortfolio on "Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia"

Quick Search

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...